key: cord-0729800-vlqiskqm
authors: Cui, Yu; Hu, Caixia; Cheng, Yi; Han, Xiaomei; Wang, Wenqing
title: Plasmapheresis: a feasible choice for bullous pemphigoid patients infected with SARS‐CoV‐2
date: 2021-09-14
journal: Int J Dermatol
DOI: 10.1111/ijd.15892
sha: 77d9ef618401955d16364645a36ca111e17b63f3
doc_id: 729800
cord_uid: vlqiskqm

Bullous pemphigoid (BP) patients were vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection because they have similar risk factors, so we should pay attention to patients with BP during the epidemic of coronavirus disease‐19 (COVID‐19). As far as treatment is concerned, many strategies for BP were changed during the epidemic. Plasmapheresis not only has been included in the guidelines for BP but also has been used successfully to rescue COVID‐19 patients, especially in severe cases. Therefore, it is a feasible choice for BP patients, especially for refractory BP patients, infected with SARS‐CoV‐2. Apart from these, we have reviewed some points for attention during the plasmapheresis session.

Introduction of treatment strategies for BP during the epidemic Bullous pemphigoid, one of the autoimmune blistering diseases (AIBDs), typically presents with tense and mostly clear blisters and erythema. Blisters often appear on the flexural aspects of the limbs and on the abdomen. Almost all patients have severe pruritus. 6 In terms of treatment, for mild BP patients, topical corticosteroids, antibiotics, and nicotinamide are recommended. Topical and systemic corticosteroids and immunosuppressive drugs are suggested for the treatment of moderate BP patients. Meanwhile, for severe BP patients, intravenous immunoglobulin (IVIG), biologic agent, and plasmapheresis might be considered. [8] [9] [10] Patients with AIBDs using immunosuppressive drugs which contain azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate, cyclosporine, cyclophosphamide, and corticosteroids (prednis[ol]one >10 mg/day) are more likely to be infected with SARS-CoV-2 and develop more severe COVID- 19 . 11 During the pandemic, these drugs should be tapered to the lowest effective dose. 12 However, if patients are positive for SARS-CoV-2, these drugs should be temporarily withdrawn, after considering the severity of AIBDs, past medical history, comorbidities, age, and severity of COVID-19, except corticosteroids, which should be reduced gradually to at least 7.5-10 mg/day to avoid abrupt termination or considerable dose reduction. 11, 13, 14 If patients using biologic agent have suspected or confirmed SARS-CoV-2 infection within 31 days, the next dose should be withdrawn or postponed (based on the potential time of viral shedding). 18 The biologic therapy can be recommended depending on the resolution of illness and/or confirmation of negative PCR testing manifesting no viral shedding 18 (Table 1 ).

In addition to the above treatments, plasmapheresis, which was proved effective for refractory BP (using systemic corticosteroids and immunosuppressant for 1 month failed to control the disease), has also been included in the guidelines for BP. [8] [9] [10] Plasmapheresis Introduction of plasmapheresis Plasmapheresis, such as plasma exchange (PE) and double filtration plasmapheresis (DFPP), was a therapeutic option for severe or intractable cases. 19 Therapeutic PE is a procedure in which blood of the patient is passed through a medical device that removes units of whole blood anticoagulated with heparin and isolates plasma from other components of blood. The plasma is removed and substituted with a replacement solution such as colloid solution (e.g., albumin and/or plasma) or a combination of crystalloid/colloid solution. Eventually, the cellular elements are then mixed with the replacement and reinfused. 20,21 DFPP is a filter-based therapeutic procedure that removes pathogenic substances from isolated plasma based on their size, which is mainly determined by molecular weight and three-dimensional configuration by plasma filters with different pore sizes. 20 In these ways, the pathologic substances such as pathologic autoantibodies, immune complexes, and cytokines will be removed. 21

We have used plasmapheresis along with glucocorticosteroid and/or immunosuppressive agents to treat severe BP patients, and the results were the reduction in serum levels of antiBP180, the alleviation of pruritus, and the disappearance of bulla, which were consistent with our expectations. 22, 23 Similar outcomes were found in other studies. 24, 25 When the clinical manifestation appears resistant to oral immunosuppression, or when additional second-line drugs produce an increasingly unfavorable side effect, it was preferable to consider a trial of plasmapheresis. 24 In addition to BP, plasmapheresis was also used in some severe dermatoses, such as severe psoriasis, connective tissue diseases, pemphigus, drug eruption, and insect and animal bite diseases. 26, 27 Similarly, in other disciplines, plasmapheresis was used in hematologic disorders, solid organ transplantation, hematopoietic stem cell transplantation, neurologic disorders, renal disorders, fulminant hepatitis, vasculitis, and so on. 20, 28 Plasmapheresis and COVID-19 During the epidemic, plasmapheresis was used successfully to rescue COVID-19 patients, especially severe cases. [29] [30] [31] [32] [33] [34] As is known to all, the level of cytokine, coagulation agent, and viral load is the most important parameter to determine the outcome of COVID-19, 31 particularly the "cytokine storm" that plays an important role in the pathophysiology of the SARS-CoV-2 infection in patients. 35 Plasmapheresis can remove toxins and deleterious inflammatory cytokines such as IL-1, IL-6, granulocyte-colony stimulating factor, tumor necrosis factor (TNF), and other inflammatory parameters to alleviate cytokine storm. 32 These cytokines' levels, such as IL-1, IL-6, and TNF-a, were correlated with the activity of BP. 36 Then removing these cytokines by plasmapheresis is a good strategy not only for COVID-19 but also for BP patients. Moreover, plasmapheresis also exerts a role in reducing the abnormal coagulation agents. 31 In addition, plasmapheresis could reduce the viral load by eliminating SARS-CoV-2 viral particles since they have a diameter of 60-140 nm and are large enough to be eliminated which is followed by the clearance of the virus. 39 Symptomatic COVID-19 mainly consists of three phases. The first is a starting phase, including the acquisition of the virus and subsequent viremia; the second is the acceleration phase, that is, virus-induced secondary damage of targeting organs and tissue including the lungs, the heart, the gastrointestinal tract, and even an overall inflammatory storm; and the third phase is the final recovery phase. 40 So, the strategies against COVID-19 should be given early in the course of the disease, just prior to the acceleration phase. 34, 40 If clinical deterioration has begun, the first few days of deterioration is also a critical point. 40 Several studies have also shown that the administration of plasmapheresis within 7-14 days of the illness onset could be associated with better outcome. 32, 39 Second, how much plasma volume is advised? A total of 2-3 liters of plasma is recommended in the plasmapheresis of BP patients, 9 and 1.5 plasma volume was suggested in the PE for severe COVID-19 patients every time. 38 In another study, 1.2 plasma volume also had a good effect on the condition. 30 In addition, we can use this formula to calculate the plasma volume, the amount of plasma replacement (l) = body weight (kg) 9 (1/13) 9 (1Àhematocrit/100) and that at least 2 liters of plasma should be administered when plasma is scarce. 41 Third, what is the replacement solution? The choice for replacement solution includes fresh frozen plasma, 5% albumin, or 0.9% saline. 29, 42 After plasmapheresis, the convalescent plasma from a recovered patient or IVIG could be transfused to the patient immediately. 38, 43, 44 Last, the frequency and the number of times of plasmapheresis depend on the patient's condition. We summarized the experience in the treatment of BP and COVID-19 patients with plasmapheresis in Tables 2 and 3 . 22, 31, [44] [45] [46] [47] Although plasmapheresis is safe and effective, special attention should be paid to its possible complications. The common complications include hypocalcemia or hypomagnesemia, hypothermia, transfusion reactions, hypotension, urticarial, infection, bleeding/hematoma, and so on. 21, 48, 49 However, after continuous observation in healthcare faculties, these side effects could be closely monitored, thus ensuring patients' safety. 48 It is noteworthy that plasmapheresis merely interrupts or delays the progression of the disease. It only removes the pathogenic substances rapidly, creating opportunities for drug treatment, so in the meantime, etiological treatment should be carried out. Moreover, given that it is an invasive and expensive treatment, the indications should be clarified. 50

Questions: True or False questions (answers provided after references) 1 The risk factors for SARS-CoV-2 infection and BP are different.

2 BP typically presents with tense and mostly clear blisters and erythema.

3 During the pandemic, all drugs for BP should be temporarily withdrawn.

4 Dapsone, doxycycline, and IVIG demonstrate beneficial effects on COVID-19. 5 The pathologic substances such as pathologic autoantibodies, immune complexes, and cytokines will be removed by plasmapheresis. 6 We have used plasmapheresis along with glucocorticosteroid and/or immunosuppressive agents to treat severe BP patients successfully.

7 Plasmapheresis could not rescue COVID-19 patients.

8 Plasmapheresis can remove toxins and deleterious inflammatory cytokines to alleviate cytokine storm.

9 Plasmapheresis is not a feasible choice for BP patients infected with SARS-CoV-2.

10 The results of plasmapheresis for severe COVID-19 are highly dependent on timing.

A novel coronavirus emerging in China -key questions for impact assessment

Word Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Pemphigoid diseases

Association of serious infections with pemphigus and pemphigoid: analysis of the Nationwide Inpatient Sample

S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update

The Autoimmune Diseases Council of Chinese Dermatologist Association

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology

Guidance from the EADV Task Force Autoimmune Blistering Diseases during the COVID-19 pandemic

Treatment considerations for patients with pemphigus during the COVID-19 pandemic

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

Use of immunosuppressants/ immunomodulators in autoimmune/inflammatory dermatologic diseases during COVID-19 pandemic-general recommendation based on available evidence

Dexamethasone in hospitalized patients with covid-19 -preliminary report

Dapsone and doxycycline could be potential treatment modalities for COVID-19

SARS-CoV-2 infection complicated by inflammatory syndrome. Could high-dose human immunoglobulin for intravenous use (IVIG) be beneficial?

COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: an Australian/New Zealand consensus statement

Safety and efficacy of plasma exchange via direct femoral vein puncture in autoimmune blistering diseases

Guidelines on the use of therapeutic apheresis in clinical practice -evidencebased approach from the Writing Committee of the American Society for Apheresis: the eighth special issue

Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines

Clinical analysis and serological antibody level detection of patinets with pemphigus and bullous pemphigoid after plasmapheresis therapy

A retrospective study of 122 cases of bullous pemphigoid

Clinical and serological responses following plasmapheresis in bullous pemphigoid: two case reports and a review of the literature

Clinical effect of plasma exchange therapy on severe bullous pemphigoid

Application of plasma exchange on treating severe dermatoses

Treatment of severe dermatoses with plasma transfusion and plasma exchange therapy

Segu ı I, de la Rubia J. Therapeutic plasma exchange: review of current indications

Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia

Therapeutic plasma exchange in a critically ill Covid-19 patient

Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: immunopathogenesis and coagulopathy

Therapeutic plasma exchange in adults with severe COVID-19 infection

The application of plasmapheresis for Covid-19 patients

Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives

Immunologic features in coronavirus disease 2019: functional exhaustion of T cells and cytokine storm

Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?

General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of corona virus disease-19

Expert consensus on special blood purification technics in patients with corona virus disease 2019

Use of convalescent plasma therapy in SARS patients in Hong Kong

High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Open Forum

Expert consensus on the application of artificial liver blood purification system in the treatment of severe and critical COVID-19 (in Chinese)

Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS)

A case of COVID-19, with cytokine storm, treated by consecutive use of therapeutic plasma exchange followed by convalescent plasma transfusion: a case report

Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection

Efficacy of therapeutic plasma exchange in severe COVID-19 patients

The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure

Plasma exchange in critically ill COVID-19 patients

Complications in patients treated with plasmapheresis in the intensive care unit

Blood Purification Specialist Committee of Pediatric Association in Chinese Medical Doctor Association. Expert consensus documents on clinical application of plasma exchange in pediatrics